NON-SMALL CELL LUNG CANCER

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can re…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for future studies. Participants had different types of …

This study tested a new oral drug, AZD3759, against standard targeted therapies for people with advanced lung cancer that has spread to the brain. About 492 adults with a specific gene mutation (EGFR) took either the new drug or a standard one. The goal was to see if AZD3759 coul…

This study tested whether adding lenvatinib to pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 623 adults with tumors showing PD-L1 levels of 1% or higher took part. The goal was to see if the combination slows c…

This study tested if a shot (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried platinum-based chemotherapy took part. The goal was to see if the …

This early-phase trial tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took participants' own immune cells, genetically modified them in a lab to target cancer cells, and infused them back a…

This early-phase study tested a new method of delivering the chemotherapy drug cisplatin directly into lung tumors during a bronchoscopy procedure. Six adults with early-stage, operable non-small cell lung cancer participated to find the safest dose. The main goal was to identify…

This study tested whether adding the drug pirfenidone (already approved for a different lung condition) to standard chemotherapy is safe and effective for people with advanced non-small cell lung cancer. 48 participants received the combination. The main goals were to find the be…

This study tested whether giving treatment based on specific genetic changes in a patient's tumor could improve outcomes for advanced lung adenocarcinoma. It involved 153 adults with stage IIIB or IV non-small cell lung cancer who had not received prior chemotherapy. Researchers …

This study tested a combination of two drugs, atezolizumab and bevacizumab, as a first treatment for people with advanced non-squamous non-small cell lung cancer that has high tumor mutations. The goal was to see if this combination could stop the cancer from growing. The study i…

This early-phase study tested a drug called RAD001 (everolimus) combined with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The goal was to find safe doses and check for side effects. Participants took RAD001 weekly …

This early-phase study tested whether adding the drug copanlisib to the standard immunotherapy durvalumab could help patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study included 11 people who had already received chemotherapy and radiat…

This study tested a new drug called DS-1062a in 137 adults with advanced or spreading non-small cell lung cancer that has certain gene changes. Participants had already tried targeted therapy and platinum chemotherapy without success. The main goal was to see how many people's tu…

This early-stage study tested a new cell therapy called PB101, made from the patient's own immune cells, combined with a standard targeted pill (EGFR-TKI) for people with advanced EGFR-mutated non-small cell lung cancer. The main goal was to check if the combination was safe and …

This early-phase study tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cancer. Researche…

This study looked at whether adding a simple blood test (liquid biopsy) to the usual tissue biopsy can help find more EGFR gene mutations in people with advanced non-small cell lung cancer. Over 500 patients were tested using both methods. The goal was to see if the combination a…

This study tested a special breathing technique during PET scans to get clearer images of lung nodules. 103 people with small lung spots (under 35 mm) took part. The goal was to see if this method helps doctors spot cancer more accurately by reducing blur from breathing.

This study tested a family-supported palliative care program for 110 adults with advanced lung cancer. The program included family education, counseling, and symptom management over 8 weeks. Researchers measured quality of life, decision-making, and emotional well-being. The goal…

This study looked back at the medical records of 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. The goal was to see how well this treatment …